在这项最新研究中，研究团队进行了体内激酶组 CRISPR 筛选，从中确定了 CDK10 是肿瘤免疫监视的关键抑制因子。 从机制上来说，CDK10 通过磷酸化 DNMT1 和 RAP80 来减少双链 RNA 和 R-loop 的积累，从而减轻由 ...

该公司的生物团队在将创新产品成功推向市场的各个方面拥有150多年的丰富经验，首席医疗和科学官Christine Ginocchio博士是分子诊断学和临床微生物学领域的世界知名专家。她曾是60多项工业和制药临床试验的主要研究者，其中包括21项体外诊断设备研究，获得了美国食品药品管理局 (FDA) 的批准。她的研究将给VedaBio带来技术支撑。

《麻省理工科技评论》从 2013 年开始报道 CRISPR 基因编辑技术，我们将它称为本世纪最大的生物技术突破。然而到目前为止，只有一种基因编辑药物获批。这种药物仅在约 40 名患有镰状细胞病的患者身上进行了商业化使用。

CRISPR has the power to correct genetic mutations, but current delivery methods are either unsafe or inefficient, keeping the technology from reaching its full medical potential. With the power to ...

CRISPR Therapeutics' stock is down 19% since December, with a slow Casgevy launch and significant R&D investments, yet strong cash reserves provide a safety net. Q4 earnings show no revenue from ...

CRISPR Therapeutics' stock decline is likely influenced by Editas Medicine's struggles, but CRISPR remains a distinct and stronger company with a promising long-term outlook. CRISPR's strategic ...

This story is part of a series on the current progression in Regenerative Medicine. This piece is part of a series dedicated to the eye and improvements in restoring vision. In 1999, I defined ...

Nine people with a rare genetic condition that causes life-threatening inflammatory reactions appear to have been cured, after taking part in the first trial of a new version of a CRISPR-based gene ...

Sam Berns was my friend. With the wisdom of a sage, he inspired me and many others about how to make the most of life. Afflicted with the rare disease called progeria, his body aged at a rapid rate, ...